Targeting of Prostate Cancer with Hyaluronan-Binding Proteins
Abstract
This study is to test if hyaluronan (HA) binding proteins (HABP), an abundant protein in cartilage, is a new category of anti-tumor substance. This hypothesis is based on the facts that: (1) the shake cartilage powder or its extracts have been widely used by patients with different tumors in USA, Europe and Asia for a decade, in believing that avascular cartilage might contain some natural anti-tumor/angiogenesis substance; (2) certain angiogenic inhibitor, such as endostatin, has HA binding domain; and (3) some hyaluronan binding proteins, such as soluble CD44 and proteins from scapular chondrocytes or have anti-tumor/angiogenesis effect. In the past year, we have purified a large quantity of hyaluronan binding proteins from bovine cartilage and test its anti-tumor and anti-angiogenesis effects. The result are promising, indicating that (1) HABP can inhibit the anchorage- dependent and independent growth of tumor cells; (2) HABP can inhibit proliferation and migration of endothelial cells in vitro and angiogenesis in vivo; (3) HABP can reduce the growth of TSU prostate cancer and other tumor in vivo; (4) HABP can inhibit the experimental lung metastasis. It seems that HABP is a good candidate for development into a new anti- tumor agent. Next year, we will focus on test HABP from human source using molecular biology approaches. The human HABP will be cloned, inserted into expression vector and transfected into prostate cancer cells or infected in established prostate tumor to see the effect of human HABP on tumor growth. The underlying molecular mechanism of HABP by which it exerts anti-tumor/angiogenesis effect will also be explored.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2001
- Accession Number
- ADA398567
Entities
People
- Lurong Zhang
Organizations
- Georgetown University